-
Posted by
Two Blokes Fri at 11:00 AM -
Filed in
Stock
-
1 view
The U.S. Keytruda market, valued at $17.87 billion in 2024, faces a projected CAGR decline of -3.12% by 2033 due to patent expiration and biosimilar competition. Keytruda's continued use in various cancer treatments, including melanoma and lung cancer, alongside innovations and new trial results, aim to mitigate these challenges and sustain market presence. The U.S. Keytruda market, valued at $17.87 billion in 2024, faces a projected CAGR decline of -3.12% by 2033 due to patent expiration and biosimilar competition. Keytruda's continued use in various cancer treatments, including melanoma and lung cancer, alongside innovations and new trial results, aim to mitigate these challenges and sustain market presence.
